Logo image of BDRX

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Fundamental Analysis

NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD

8.51  +7.65 (+889.53%)

Fundamental Rating

1

BDRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. BDRX may be in some trouble as it scores bad on both profitability and health. BDRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDRX has reported negative net income.
BDRX had a negative operating cash flow in the past year.
In the past 5 years BDRX always reported negative net income.
In the past 5 years BDRX always reported negative operating cash flow.
BDRX Yearly Net Income VS EBIT VS OCF VS FCFBDRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.76%, BDRX is in line with its industry, outperforming 57.87% of the companies in the same industry.
With a Return On Equity value of -68.84%, BDRX perfoms like the industry average, outperforming 55.88% of the companies in the same industry.
Industry RankSector Rank
ROA -38.76%
ROE -68.84%
ROIC N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
BDRX Yearly ROA, ROE, ROICBDRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

BDRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDRX Yearly Profit, Operating, Gross MarginsBDRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BDRX has more shares outstanding
Compared to 1 year ago, BDRX has a worse debt to assets ratio.
BDRX Yearly Shares OutstandingBDRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
BDRX Yearly Total Debt VS Total AssetsBDRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

BDRX has an Altman-Z score of -10.72. This is a bad value and indicates that BDRX is not financially healthy and even has some risk of bankruptcy.
BDRX's Altman-Z score of -10.72 is on the low side compared to the rest of the industry. BDRX is outperformed by 74.86% of its industry peers.
BDRX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
BDRX has a worse Debt to Equity ratio (0.07) than 63.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -10.72
ROIC/WACCN/A
WACC7.94%
BDRX Yearly LT Debt VS Equity VS FCFBDRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

BDRX has a Current Ratio of 1.75. This is a normal value and indicates that BDRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.75, BDRX is doing worse than 79.20% of the companies in the same industry.
A Quick Ratio of 1.75 indicates that BDRX should not have too much problems paying its short term obligations.
The Quick ratio of BDRX (1.75) is worse than 78.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.75
BDRX Yearly Current Assets VS Current LiabilitesBDRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.03% over the past year.
Looking at the last year, BDRX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)97.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.4%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 12.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2023 2024 2025 2026 2027 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BDRX. In the last year negative earnings were reported.
Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDRX Price Earnings VS Forward Price EarningsBDRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDRX Per share dataBDRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

BDRX's earnings are expected to grow with 12.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y12.21%

More info and screens

0

5. Dividend

5.1 Amount

BDRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (7/31/2025, 10:27:41 AM)

8.51

+7.65 (+889.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)09-22 2025-09-22
Inst Owners7.7%
Inst Owner Change46.02%
Ins Owners0.48%
Ins Owner ChangeN/A
Market Cap24.60M
Analysts85.71
Price Target18.36 (115.75%)
Short Float %N/A
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 6.88
EV/EBITDA N/A
EPS(TTM)-4.29
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-6.03
FCFYN/A
OCF(TTM)-5.67
OCFYN/A
SpS0
BVpS3.85
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.76%
ROE -68.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 304.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.75
Quick Ratio 1.75
Altman-Z -10.72
F-Score3
WACC7.94%
ROIC/WACCN/A
Cap/Depr(3y)138.58%
Cap/Depr(5y)102.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.4%
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-83.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.62%
OCF growth 3YN/A
OCF growth 5YN/A